TOBI Podhaler Approval History
FDA Approved: Yes (First approved March 22, 2013)
Brand name: TOBI Podhaler
Generic name: tobramycin
Dosage form: Inhalation Powder
Company: Novartis Pharmaceuticals Corporation
Treatment for: Cystic Fibrosis
TOBI Podhaler (tobramycin inhalation powder) is an antibacterial aminoglycoside indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.
Development History and FDA Approval Process for TOBI Podhaler
|Mar 24, 2013||FDA Approves TOBI Podhaler to Treat a Type of Bacterial Lung Infection in Cystic Fibrosis Patients|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.